-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gene sequencing refers to the analysis of base sequences in DNA or RNA fragments through certain technical means, so as to provide support for biological and medical research findings
.
In recent years, the size of the gene sequencing market has developed rapidly.
According to data, the growth rate of the global gene sequencing market generally exceeded 10% from 2010 to 2019.
In 2019, the global gene sequencing market size was approximately US$12.
6 billion
.
The industry believes that with the rapid development of gene sequencing technology, huge changes will take place in the fields of clinical diagnosis, medicine, and individualized treatment, and as the society pays more and more attention to the gene sequencing application industry, various fields are based on genes.
The demand for sequencing applications will also increase
.
It is expected that the scale of the global gene sequencing market will continue to grow rapidly from 2021 to 2026, and it will exceed US$40 billion by 2026
.
In recent years, China's gene sequencing industry has also developed rapidly due to the impact of the general environment
.
During the period from 2011 to 2018, the overall market size of China's gene sequencing industry has been increasing year by year, with an average annual compound growth rate of as high as 35.
45%
.
It is worth noting that the state has also promulgated a number of regulations and policies, while regulating the development of the industry, it continues to contribute to the development of China's gene sequencing industry
.
For example, the "Notice on the Pilot Work of Assisted Reproductive Institutions to Launch High-throughput Gene Sequencing Preimplantation Embryo Genetic Diagnosis Clinical Application", it is planned to invest 60 billion yuan in the field of precision medicine by 2030
.
With favorable policies, many related companies are also accelerating their deployment in the gene sequencing market
.
For example, on September 29, Zhenmai Bio announced the completion of 140 million yuan in Series B financing.
The investors are Xinxi Capital and Chishi Liaoyuan
.
It is understood that this round of investment by Zhenmai Bio is mainly to expand the market and applications, increase research and development efforts and upgrade the platform
.
Public information shows that Zhenmai Bio is a high-tech company that develops single-molecule gene sequencing
.
It focuses on the research and development of the upstream platform of gene sequencing, and strives to overcome the hard technology of the gene platform
.
In 2019, Zhenmai Biomolecular Sequencer passed the medical device registration inspection and medical device filing
.
At present, Zhenmai Bio has established a GMP production line, and has passed the trial operation, and has entered the stage of independent production
.
On September 30, Jinshi Technology also announced the completion of a Series B financing of over 100 million yuan
.
This round of financing was led by Huachuang Capital, with Sequoia China, Sinopharm Capital, Rongan Ventures, Huiyuan Capital, and Trend Growth Fund, as well as old shareholders Weidu Capital and Darun Capital.
The funds will be used for Nanopore.
R&D and commercialization of gene sequencers
.
From an overall point of view, the current product structure of China's gene sequencing industry companies is different
.
For example, the product structure of Dean Diagnostics and BGI Gene, the leading companies in gene sequencing, has certain differences
.
Among them, Daan Gene is mainly engaged in the research, development and application of fluorescent PCR detection technology
.
BGI, genetic testing provides genomics diagnosis
.
Dean Diagnostics, an independent third-party medical diagnostic service platform
.
In general, with the continuous development of domestic gene sequencing technology, the gradual maturity of cloud computing, supercomputing and other technologies, the gradual completion of gene bank infrastructure, and the further improvement of relevant policies and regulations, the domestic genetic testing industry will continue to grow at a high speed.
Growth
.
The industry predicts that by 2022, China's genetic testing market is expected to exceed 30 billion yuan, and affected by this, the performance of related companies may also usher in a new round of growth
.
.
In recent years, the size of the gene sequencing market has developed rapidly.
According to data, the growth rate of the global gene sequencing market generally exceeded 10% from 2010 to 2019.
In 2019, the global gene sequencing market size was approximately US$12.
6 billion
.
The industry believes that with the rapid development of gene sequencing technology, huge changes will take place in the fields of clinical diagnosis, medicine, and individualized treatment, and as the society pays more and more attention to the gene sequencing application industry, various fields are based on genes.
The demand for sequencing applications will also increase
.
It is expected that the scale of the global gene sequencing market will continue to grow rapidly from 2021 to 2026, and it will exceed US$40 billion by 2026
.
In recent years, China's gene sequencing industry has also developed rapidly due to the impact of the general environment
.
During the period from 2011 to 2018, the overall market size of China's gene sequencing industry has been increasing year by year, with an average annual compound growth rate of as high as 35.
45%
.
It is worth noting that the state has also promulgated a number of regulations and policies, while regulating the development of the industry, it continues to contribute to the development of China's gene sequencing industry
.
For example, the "Notice on the Pilot Work of Assisted Reproductive Institutions to Launch High-throughput Gene Sequencing Preimplantation Embryo Genetic Diagnosis Clinical Application", it is planned to invest 60 billion yuan in the field of precision medicine by 2030
.
With favorable policies, many related companies are also accelerating their deployment in the gene sequencing market
.
For example, on September 29, Zhenmai Bio announced the completion of 140 million yuan in Series B financing.
The investors are Xinxi Capital and Chishi Liaoyuan
.
It is understood that this round of investment by Zhenmai Bio is mainly to expand the market and applications, increase research and development efforts and upgrade the platform
.
Public information shows that Zhenmai Bio is a high-tech company that develops single-molecule gene sequencing
.
It focuses on the research and development of the upstream platform of gene sequencing, and strives to overcome the hard technology of the gene platform
.
In 2019, Zhenmai Biomolecular Sequencer passed the medical device registration inspection and medical device filing
.
At present, Zhenmai Bio has established a GMP production line, and has passed the trial operation, and has entered the stage of independent production
.
On September 30, Jinshi Technology also announced the completion of a Series B financing of over 100 million yuan
.
This round of financing was led by Huachuang Capital, with Sequoia China, Sinopharm Capital, Rongan Ventures, Huiyuan Capital, and Trend Growth Fund, as well as old shareholders Weidu Capital and Darun Capital.
The funds will be used for Nanopore.
R&D and commercialization of gene sequencers
.
From an overall point of view, the current product structure of China's gene sequencing industry companies is different
.
For example, the product structure of Dean Diagnostics and BGI Gene, the leading companies in gene sequencing, has certain differences
.
Among them, Daan Gene is mainly engaged in the research, development and application of fluorescent PCR detection technology
.
BGI, genetic testing provides genomics diagnosis
.
Dean Diagnostics, an independent third-party medical diagnostic service platform
.
In general, with the continuous development of domestic gene sequencing technology, the gradual maturity of cloud computing, supercomputing and other technologies, the gradual completion of gene bank infrastructure, and the further improvement of relevant policies and regulations, the domestic genetic testing industry will continue to grow at a high speed.
Growth
.
The industry predicts that by 2022, China's genetic testing market is expected to exceed 30 billion yuan, and affected by this, the performance of related companies may also usher in a new round of growth
.
